3-Methyl-3-isopropyl-oxetan | 35737-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 英文名称: 3-Methyl-3-isopropyl-oxetan
• 英文别名: Oxetane, 3-methyl-3-(1-methylethyl)；3-methyl-3-propan-2-yloxetane
• CAS: 35737-68-9
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: DESPTAAIBOOLQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Methyl-3-isopropyl-oxetan 、 硫脲 、 高氯酸 以30%的产率得到
  参考文献：
  名称：

  TURYANSKAYA, A. M.;GREN, A. I.;BACHERIKOV, V. A., VINITI 792-85

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(bromomethyl)-2,3-dimethylbutan-1-ol 、 sodium hydroxide 以20%的产率得到
  参考文献：
  名称：

  TURYANSKAYA, A. M.;GREN, A. I.;BACHERIKOV, V. A., VINITI 792-85

  摘要：

  DOI：

文献信息

• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2016191172A1

  公开（公告）日：2016-12-01

  Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公式(I)的化合物是成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制FGFR治疗的疾病。还披露了包含此类化合物的药物组合物以及制备此类化合物的过程。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• Purinone Derivatives as Tyrosine Kinase Inhibitors
  申请人：Principia Biopharma Inc.

  公开号：US20140142099A1

  公开（公告）日：2014-05-22

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供了一些酪氨酸激酶抑制剂及其药用盐，特别是BLK、BMX、EGFR、HER2、HER4、ITK、TEC、BTK和TXK，因此适用于治疗通过抑制酪氨酸激酶可治疗的疾病，如自身免疫疾病、癌症和炎症性疾病。还提供了含有这些化合物和药用盐的药物组合物，以及制备这些化合物和药用盐的方法。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175560A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R 2 , R 3 , R 4 , p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类钠通道抑制剂化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由式I给出：其中X、Y、Z、R2、R3、R4、p和q如本文所述，以及制备和使用该化合物的方法以及含有该化合物的药物组合物。
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION, LIQUID CRYSTAL POLYMERIZATION FILM-KIND THEREOF AND USE THEREOF
  申请人：JNC CORPORATION

  公开号：US20170174992A1

  公开（公告）日：2017-06-22

  An object is to provide a polymerizable liquid crystal compound, a polymerizable liquid crystal composition containing the compound and liquid crystal polymerization film-kind capable of controlling chromatic dispersion characteristics and having low positive chromatic dispersion characteristics. An aspect can be exemplified in which the polymerizable liquid crystal compound is represented by formula (1): in which, in formula (1), G is a group composed of a quinoline skeleton, an isoquinoline skeleton, a quinoxaline skeleton or a quinazoline skeleton, A 1 is 1,4-phenylene or 1,4-cyclohexylene, Z 1 is a connecting group, m is an integer from 0 to 3, and R 1 is a group containing a polymerizable group.

  提供一种可聚合的液晶化合物，包含该化合物的可聚合液晶组合物以及能够控制色散特性并具有低正色散特性的液晶聚合膜。一种例子是该可聚合液晶化合物由式(1)表示：其中，在式(1)中，G是由喹啉骨架、异喹啉骨架、喹啉骨架或喹嗪骨架组成的基团，A1为1,4-苯基或1,4-环己基，Z1为连接基，m为0至3的整数，R1为含有可聚合基团的基团。